Multifocal Contact Lens With Cycloplegic Buffer for Myopia Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing or controlling myopia in young children, such as orthokeratology and long-acting mydriatics, are uncomfortable and pose risks of side effects, while multifocal contact lenses and cycloplegic agents are not optimally formulated to address myopia progression effectively.

Innovation Solution

A multifocal contact lens with concentric regions of varying diopters and a cycloplegic agent in a buffer solution, with controlled concentration, is designed to relax the ciliary muscle and moderate myopia progression, combined with blue-light and UV-blocking agents for enhanced comfort and safety.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If orthokeratology is used to prevent or control myopia, then myopia progression can be controlled, but the wearer experiences high external pressure and discomfort

Engineering Contradiction:

Improvemyopia control effectivenessVSAvoidwearing comfort

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the optical parameters of the contact lens by incorporating multiple focal regions with different diopter values. The central region has one diopter value while the annular region has a different diopter value, creating a multifocal structure that modifies how light focuses on the retina to control myopia progression without requiring high external pressure

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The contact lens is segmented into distinct functional regions: a central region and an annular region surrounding it. Each region has different optical properties (different diopters) to perform different functions - the central region for clear distance vision and the annular region for peripheral myopia control, thereby achieving therapeutic effect without compromising comfort

Inventive Principle:

Principle #1Segmentation

2Reliability

If long-acting mydriatics are applied to correct pseudomyopia, then pseudomyopia can be corrected, but higher concentration doses are required which increase the probability of drug side effects

Engineering Contradiction:

Improvepseudomyopia correction effectivenessVSAvoiddrug side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses a buffer solution containing a cycloplegic agent at a specifically controlled low concentration (0.01-2% w/v) as an intermediary medium. This buffer solution is applied to the contact lens, which then delivers the medication to the eye. The buffer solution acts as a carrier that maintains drug stability while controlling release, achieving therapeutic effect at lower concentrations and reducing side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the concentration parameter of the cycloplegic agent from traditional high doses to a specifically controlled low range (0.01-2% w/v). This parameter change, combined with the buffer solution formulation, maintains therapeutic effectiveness while significantly reducing the probability of drug side effects

Inventive Principle:

Principle #35Parameter changes

3Reliability

If multifocal contact lenses are used to control myopia, then peripheral images can be focused in front of the retina, but the lenses require complex multifocal design with multiple diopter regions

Engineering Contradiction:

Improvemyopia progression controlVSAvoidlens design complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Different regions of the contact lens are assigned different optical qualities (different diopter values). The central region has one diopter value optimized for central vision, while the annular region has a different diopter value optimized for peripheral myopia control. This local differentiation of optical quality achieves effective myopia control while maintaining a relatively simple overall lens design

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solution effectively prevents myopia progression by focusing peripheral images in front of the retina, reducing axial elongation, while minimizing drug side effects and enhancing comfort with improved oxygen permeability and light protection.

Implementation Method 1

The multifocal contact lens includes a central region and at least one annular region, wherein a diopter of the annular region is different from a diopter of the central region

Methodology Applied

Scientific EffectRefraction: Refraction

Implementation Method 2

The buffer solution includes a cycloplegic agent

Methodology Applied

Scientific EffectPharmacological action of cycloplegic agent:

Implementation Method 3

A composition for manufacturing the multifocal contact lens includes a blue-light blocking agent

Methodology Applied

Scientific EffectLight absorption: Absorption (EM radiation)

Implementation Method 4

A composition for manufacturing the multifocal contact lens includes a blue-light blocking agent

Methodology Applied

Scientific EffectLight absorption: Absorption (EM radiation)

Data Source

PatentUS12607877B2Contact lens product

Publication Date: 2026.04.21 LARGAN MEDICAL CO LTD

AI summary

A contact lens product includes a multifocal contact lens and a buffer solution. The multifocal contact lens includes a central region and at least one annular region. The annular region concentrically surrounds the central region. A diopter of the annular region is different from a diopter of the central region. The multifocal contact lens is immersed in the buffer solution, and the buffer solution includes a cycloplegic agent.